TrialNCT07222332
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
- Status
- RECRUITING
- Phase
- PHASE3
- Last update posted
- 09/04/2026
- Start
- 02/05/2026
- Sponsor
- Eli Lilly and Company
- Specialties
- diabetes
Conditions: Diabetes Mellitus, Type 1
Brief summary
The purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last about 60 weeks.
Protocol documents and results are not hosted here. Verify every detail on ClinicalTrials.gov.